SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing elevated trading volume and renewed buyout speculation as investors track a shift toward capital-efficient partnerships following the closure of its internal discovery facility. The community remains focused on potential M&A catalysts, robust Orladeyo sales, and the significant short interest that traders believe could fuel a sharp rally if positive news emerges.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the market reacts to a 75-million-share offering designed to strengthen the balance sheet and satisfy equity-matching requirements for a government loan for its Georgia manufacturing plant. While the company simultaneously reported a positive revenue forecast, the community is sharply divided, with bulls viewing the capital raise as a strategic move to unlock long-term growth and bears expressing frustration over the timing and resulting share dilution.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is trending as investors focus on the company's dual clinical and legal catalysts, specifically the progress of the Imdusiran Hepatitis B program and ongoing patent litigation against major pharmaceutical firms. The community is actively debating the potential for a favorable settlement with Pfizer following the Moderna payout, while simultaneously expressing frustration over the stock's stagnant price action and lack of clear communication from leadership.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is trending following a massive Q3 earnings beat and raised full-year guidance, with investors highlighting its critical role in the AI infrastructure and memory demand ecosystem. Community discussion is focused on the stock's positioning as an NVIDIA AI Factory partner, though some traders remain cautious regarding recent share dilution and dependency on memory pricing cycles.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is trending as traders analyze a flurry of bullish options activity and speculative positioning around potential energy sector recovery. The market conversation remains heavily fixated on the ongoing Strait of Hormuz instability, with the community actively debating whether recent diplomatic signals and tanker traffic shifts represent a durable easing of supply risks or merely temporary volatility.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following a massive $19 billion, 20-year lease agreement with AI giant Anthropic for its Kentucky data center campus, a deal that signals the companys definitive pivot from crypto mining to critical AI infrastructure. While the community is debating whether the stock's volatile price action reflects a 'sell-the-news' event or aggressive institutional manipulation, long-term investors remain highly optimistic about TeraWulf's status as a top-tier power provider for the AI sector.

Phoenix Asia Holdings Ltd. engages in the substructure works and other construction services. It offers site formation, ground investigation and foundation work through it subsidiary. The company was founded on August 9, 2024 and is headquartered in Hong Kong.

Phoenix Asia Holdings Ltd.

Phoenix Asia Holdings is capturing significant investor attention as community members trade the stock based on its history of volatile, low-float price swings and frequent volatility halts. Discussions are currently dominated by retail traders debating the stock's potential for explosive squeezes versus skepticism over its long-term stability and underlying business performance.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is currently a major point of discussion as traders debate the potential impact of pending regulatory clarity and the long-term utility of the asset within the global banking system. The community remains deeply divided, with bulls pointing to institutional adoption and project milestones, while skeptics express frustration over price performance and ongoing market volatility.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant community backlash as investors vent frustrations over prolonged price stagnation and alleged mismanagement, fueling intense debate between those hoping for a bottom and those claiming the project is a value trap. Investors are increasingly vocal about the lack of support compared to other major chains, with many expressing deep disappointment over the discrepancy between network fundamentals and the coin's technical performance.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

Royal Caribbean is seeing significant momentum as investors digest a wave of positive analyst sentiment and dividend hikes, keeping the stock in the spotlight despite broader market volatility. The community remains hyper-focused on its robust booking demand and yield growth, with active debates centered on whether cruise lines are decoupling from broader travel sector headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Korro Bio (KRRO) to Release Quarterly Earnings on Wednesday

Korro Bio (NASDAQ:KRRO) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

What Makes Korro Bio, Inc. (KRRO) a New Buy Stock

Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five hav...

Korro Bio (NASDAQ:KRRO) Stock Price Down 0.8%  - Should You Sell?

Korro Bio (NASDAQ:KRRO) Stock Price Down 0.8% - Here's Why...

JPMorgan Chase & Co. Buys 196,079 Shares of Korro Bio, Inc. $KRRO

JPMorgan Chase & Co. grew its stake in Korro Bio, Inc. (NASDAQ:KRRO - Free Report) by 6,185.5% during the third quarter, according to the company in its most recent filing with the Securities and...

Korro Bio, Inc. (NASDAQ:KRRO) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rati...

Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook

Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.read more...

Korro Bio (NASDAQ:KRRO) Rating Increased to Outperform at Raymond James Financial

Raymond James Financial upgraded Korro Bio from a "market perform" rating to an "outperform" rating and set a $23.00 price target for the company in a research report on Friday...

Insider Buying: Korro Bio (NASDAQ:KRRO) Major Shareholder Buys 207,100 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) major shareholder Scott Sandell acquired 207,100 shares of Korro Bio stock in a transaction that occurred on Tuesday, March 10th. The shares were...

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.49
Prev Close	$14.06
Open	$14.06
Dividend Yield	0.00%
50-Day Moving Average	$12.17
Beta	2.61
Avg. Volume	253,339.00
PE Ratio	-1.24

52-Week High	$55.89
52-Week Low	$5.20
Market Capitalization	$202.78M
EPS (Annual)	-$12.48
Price to Book	1.75
Revenue Per Employee	$110,206.90

Feed

News

Sentiment

Earnings

Fundamentals

Info

KRROKorro Bio Inc

Latest KRRO News